Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.

ABSTRACT:

Background

Three- and five-year progression-free survival (PFS) for low-risk meningioma managed with surgery and observation reportedly exceeds 90%. Herewith we summarize outcomes for low-risk meningioma patients enrolled on NRG/RTOG 0539.

Methods

This phase II trial allocated patients to one of three groups per World Health Organization grade, recurrence status, and resection extent. Low-risk patients had either gross total (GTR) or subtotal resection (STR) for a newly diagnosed grade 1 meningioma and were observed after surgery. The primary endpoint was 3-year PFS. Adverse events (AEs) were scored using Common Terminology Criteria for Adverse Events (CTCAE) version 3.

Results

Among 60 evaluable patients, the median follow-up was 9.1 years. The 3-, 5-, and 10-year ra

SUBMITTER: Rogers CL 

PROVIDER: S-EPMC9825319 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature